当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Luisa Cioci, La Mont Barlow, Edan Shapiro, Jennifer Ahn, Mitchell Benson, Guarionex J De Castro and James Mc Kiernan
Objective: The purpose of the current study is to perform a standardized comparison of original and internal repeat pathology reviews of identical bladder specimens to identify discrepancies and characterize the impact of repeat review on treatment decisions as well as identify patients most likely to benefit from this practice.
Materials/Methods: Ninety-one patients with an outside diagnosis of urothelial cancer of the bladder were referred to our institution for repeat review of 91 bladder resection specimens and biopsies.
A discrepancy in either the presence or absence of muscularis propria and presence of invasive disease in the muscularis propria was deemed a “treatment-altering” characteristic, while presence of carcinoma in situ, lymphovascular invasion, or micropapillary features was deemed a “clinically-significant” characteristic.
Results: After repeat review at our institution, 29.7% (27) specimens had treatment altering discrepancies, and 61.5% (56) specimens had at least one clinically-significant discrepancy.
Conclusion: Repeat review of referred bladder specimens frequently impacts treatment decisions in patients with urothelial carcinoma.